Nakano H - Search Results

1

UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug.

Oneyama C, Nakano H, Sharma SV. Oneyama C, et al. Among authors: nakano h. Oncogene. 2002 Mar 27;21(13):2037-50. doi: 10.1038/sj.onc.1205271. Oncogene. 2002. PMID: 11960376

2

Synthetic inhibitors of proline-rich ligand-mediated protein-protein interaction: potent analogs of UCS15A.

Oneyama C, Agatsuma T, Kanda Y, Nakano H, Sharma SV, Nakano S, Narazaki F, Tatsuta K. Oneyama C, et al. Among authors: nakano s, nakano h. Chem Biol. 2003 May;10(5):443-51. doi: 10.1016/s1074-5521(03)00101-7. Chem Biol. 2003. PMID: 12770826

3

Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis.

Hashimoto S, Hirose M, Hashimoto A, Morishige M, Yamada A, Hosaka H, Akagi K, Ogawa E, Oneyama C, Agatsuma T, Okada M, Kobayashi H, Wada H, Nakano H, Ikegami T, Nakagawa A, Sabe H. Hashimoto S, et al. Among authors: nakano h. Proc Natl Acad Sci U S A. 2006 May 2;103(18):7036-41. doi: 10.1073/pnas.0509166103. Epub 2006 Apr 24. Proc Natl Acad Sci U S A. 2006. PMID: 16636290 Free PMC article.

4

Drug-target identification from total cellular lysate by drug-induced conformational changes.

Nishiya Y, Shibata K, Saito S, Yano K, Oneyama C, Nakano H, Sharma SV. Nishiya Y, et al. Among authors: nakano h. Anal Biochem. 2009 Feb 15;385(2):314-20. doi: 10.1016/j.ab.2008.11.034. Epub 2008 Dec 6. Anal Biochem. 2009. PMID: 19103144

5

Development of a potent and selective FLT3 kinase inhibitor by systematic expansion of a non-selective fragment-screening hit.

Nakano H, Hasegawa T, Imamura R, Saito N, Kojima H, Okabe T, Nagano T. Nakano H, et al. Bioorg Med Chem Lett. 2016 May 1;26(9):2370-4. doi: 10.1016/j.bmcl.2016.03.006. Epub 2016 Mar 3. Bioorg Med Chem Lett. 2016. PMID: 26995531

6

hnRNP L enhances sensitivity of the cells to KW-2189.

Taguchi F, Kusaba H, Asai A, Iwamoto Y, Yano K, Nakano H, Mizukami T, Saijo N, Kato H, Nishio K. Taguchi F, et al. Among authors: nakano h. Int J Cancer. 2004 Feb 20;108(5):679-85. doi: 10.1002/ijc.11616. Int J Cancer. 2004. PMID: 14696094 Free article.

7

Theoretical Analysis of Activity Cliffs among Benzofuranone-Class Pim1 Inhibitors Using the Fragment Molecular Orbital Method with Molecular Mechanics Poisson-Boltzmann Surface Area (FMO+MM-PBSA) Approach.

Watanabe C, Watanabe H, Fukuzawa K, Parker LJ, Okiyama Y, Yuki H, Yokoyama S, Nakano H, Tanaka S, Honma T. Watanabe C, et al. Among authors: nakano h. J Chem Inf Model. 2017 Dec 26;57(12):2996-3010. doi: 10.1021/acs.jcim.7b00110. Epub 2017 Dec 1. J Chem Inf Model. 2017. PMID: 29111719

8

Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine.

Nakano H, Omura S. Nakano H, et al. J Antibiot (Tokyo). 2009 Jan;62(1):17-26. doi: 10.1038/ja.2008.4. Epub 2009 Jan 9. J Antibiot (Tokyo). 2009. PMID: 19132059 Review.

9

Sertraline, chlorprothixene, and chlorpromazine characteristically interact with the REST-binding site of the corepressor mSin3, showing medulloblastoma cell growth inhibitory activities.

Kurita JI, Hirao Y, Nakano H, Fukunishi Y, Nishimura Y. Kurita JI, et al. Among authors: nakano h. Sci Rep. 2018 Sep 13;8(1):13763. doi: 10.1038/s41598-018-31852-1. Sci Rep. 2018. PMID: 30213984 Free PMC article.

10

Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.

Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H, Okabe T, Nagano T. Nakano H, et al. Bioorg Med Chem Lett. 2015 Dec 15;25(24):5687-93. doi: 10.1016/j.bmcl.2015.10.098. Epub 2015 Oct 31. Bioorg Med Chem Lett. 2015. PMID: 26547690

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,714 results

Search Page